Skip to content
  • Argentina
  • Brazil
  • Canada
  • Chile
  • Colombia
  • Europe
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Korea
  • Mexico
  • Perú
  • Russia
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Vietnam
  • France
    • +34 96 390 53 10 Request Information
    • +34 96 390 53 10 Request Information
    FranceFrance
    • France
      • Part of brands: |
        • Nous Vous Guidons
          • Fertilité
          • Prevent inherited diseases
          • Worry-free pregnancy
        • Santé Reproductive
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • POC
            • SAT
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • À Propos de Nous
          • Igenomix Recherche
          • À propos d’Igenomix
        • Webinaires
        Genomics Precision Diagnostic > Hematology Precision Panel > Congenital Afibrinogenemia Precision Panel

        Congenital Afibrinogenemia Precision Panel

        Congenital fibrinogen disorders are a group of most frequent rare coagulation disorders, characterized by deficiency or defects in fibrinogen molecules. Congenital Afibrinogenemia is quantitative defect in fibrinogen resulting from mutations that affect plasma fibrinogen concentration and are frequently associated with a bleeding diathesis.
        Overview
        Indication
        Clinical Utility
        Genes & Diseases
        Methodology
        References

        Overview

        • Congenital fibrinogen disorders are a group of most frequent rare coagulation disorders, characterized by deficiency or defects in fibrinogen molecules. Congenital Afibrinogenemia is quantitative defect in fibrinogen resulting from mutations that affect plasma fibrinogen concentration and are frequently associated with a bleeding diathesis. Fibrinogen is a glycoprotein that is synthesized in the liver and circulates in the plasma and its physiologic function is in hemostasis. At the end of the coagulation cascade, fibrinogen is converted into fibrin creating a fibrin clot. It is involved as well in platelet aggregation and fibrinolysis. These disorders are generally inherited in an autosomal recessive pattern.  

        • The Igenomix Congenital Afibrinogenemia Precision Panel can be used to make an accurate and directed diagnosis as well as a differential diagnosis of recurrent bleeding ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.

        Indication

        • The Igenomix Congenital Afibrinogenemia Precision Panel is indicated for those patients with a clinical suspicion or diagnosis with or without the following manifestations: 
          • Umbilical cord bleeding present at birth and postpartum hemorrhage 
          • Epistaxis (nose bleeding) 
          • Hemarthrosis (bleeding in joint space) 
          • Gastrointestinal bleeding 
          • Menorrhagia 
          • Traumatic and surgical bleeding 
          • Intracranial hemorrhage in rare cases 
          • Recurrent spontaneous abortions may occur in affected female patients. 

        Clinical Utility

        The clinical utility of this panel is: 

        • The genetic and molecular confirmation for an accurate clinical diagnosis of a symptomatic patient.  
        • Early initiation of treatment with a multidisciplinary team in the form of medical therapy with fibrinogen replacement therapy, and continuous monitoring for possible liver transplantation. 
        • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance. 
        • Improvement of delineation of genotype-phenotype correlation.   

        Genes & Diseases

        See all genes and diseases

        GENE 

        OMIM DISEASES 

        INHERITANCE* 

        % GENE COVERAGE (20X) 

        HGMD** 

        FGA 

        Congenital 
        Hypofibrinogenemia, 
        Familial
         Afibrinogenemia , 
        Familial 
        Dysfibrinogenemia 

        AD,AR 

        100 

        153 of 154 

        FGB 

        Congenital
         Hypofibrinogenemia, 
        Familial 
        Afibrinogenemia ,
         
        Familial 
        Dysfibrinogenemia 

        AR 

        99.97 

        92 of 93 

        FGG 

        Congenital 
        Hypofibrinogenemia, 
        Familial 
        Afibrinogenemia , 
        Familial
         Dysfibrinogenemia 

        AR 

        99.95 

        136 of 138 

         * Inheritance: AD: Autosomal Dominant; AR: Autosomal Recessive; X: X linked; XLR: X linked Recessive; Mi: Mitochondrial; Mu: Multifactorial 

        ** HGMD: Number of clinically relevant mutations according to HGMD 

        Methodology

        References

        See scientific referrals

        Zhang, Y., Zuo, X., & Teng, Y. (2020). Women With Congenital Hypofibrinogenemia/Afibrinogenemia: From Birth to Death. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 26, 1076029620912819. https://doi.org/10.1177/1076029620912819 

        al-Mondhiry, H., & Ehmann, W. C. (1994). Congenital afibrinogenemia. American journal of hematology, 46(4), 343–347. https://doi.org/10.1002/ajh.2830460416 

        de Moerloose, P., Casini, A., & Neerman-Arbez, M. (2013). Congenital fibrinogen disorders: an update. Seminars in thrombosis and hemostasis, 39(6), 585–595. https://doi.org/10.1055/s-0033-1349222 

        Stanciakova, L., Kubisz, P., Dobrotova, M., & Stasko, J. (2016). Congenital afibrinogenemia: from etiopathogenesis to challenging clinical management. Expert review of hematology, 9(7), 639–648. https://doi.org/10.1080/17474086.2016.1200967 

        Neerman-Arbez, M., & Casini, A. (2018). Clinical Consequences and Molecular Bases of Low Fibrinogen Levels. International Journal Of Molecular Sciences, 19(1), 192. doi: 10.3390/ijms19010192 

        Asselta, R., Duga, S., & Tenchini, M. (2006). The Molecular Basis Of Quantitative Fibrinogen Disorders. Journal Of Thrombosis And Haemostasis, 4(10), 2115-2129. Doi: 10.1111/J.1538-7836.2006.02094.X 

         

        BROCHURE

        Download

        Request Information


        • reCAPTCHA demo: Simple page

        Fertilité

        Fertilité
        Éviter les maladies génétiques

        Test prénatal non-invasif

        Pour voir le certificat d'accréditation, l'annexe technique associée et la liste des tests accrédités, cliquez sur ce lien.

        Nos services

        Nos services
        Patients
        D'envoyer les échantillons
        Manuel d'utilisateur

        À propos d’Igenomix

        À propos d’Igenomix
        Igenomix dans le monde
        Quality
        Work with us

        SUIVRE IGENOMIX

          + 96 390 53 10
        Écrivez-nous
        • Argentina
        • Brazil
        • Canada
        • Chile
        • Colombia
        • Europe
        • France
        • Germany
        • India
        • Italy
        • Japan
        • Korea
        • Mexico
        • Perú
        • Russia
        • Spain
        • Taiwan
        • The Middle East
        • Turkey
        • United Kingdom
        • United States
        • Vietnam
        France

        [2021] © Igenomix Politique de confidentialité Politique de qualité Note juridique Politique de cookiesActualités et presse 

        Demander des informations


        • reCAPTCHA demo: Simple page

        • Nous Vous Guidons
          • Fertilité
          • Prevent inherited diseases
          • Worry-free pregnancy
        • Santé Reproductive
          • Specialists
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • POC
            • SAT
          • Patients
            • ALICE
            • EMMA
            • ERA
            • EndomeTRIO
            • EMBRACE
            • CGT
            • NACE
            • PGT-A
            • PGT-M
            • SAT
            • POC
        • À Propos de Nous
          • Igenomix Recherche
          • À propos d’Igenomix
        • Webinaires
        • France
        • +34 96 390 53 10 Request Information

        We are using cookies to give you the best experience on our website.

        You can find out more about which cookies we are using or switch them off in settings.

        France
        Powered by  GDPR Cookie Compliance
        Privacy Overview

        This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

        Strictly Necessary Cookies

        Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

        If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.